Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials.
Subhash BanerjeeAmita SinghBora TokluJames J DiNicolantonioKevin CroceFrederick FeitDeepak L BhattPublished in: Open heart (2014)
In patients undergoing PCI, addition of cilostazol to DAPT results in decreased platelet reactivity and a significant reduction in CV outcomes including ST, even in the drug-eluting stent era.
Keyphrases
- patients undergoing
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- clinical trial
- coronary artery bypass grafting
- atrial fibrillation
- open label
- double blind
- coronary artery bypass
- metabolic syndrome
- randomized controlled trial
- placebo controlled
- left ventricular
- insulin resistance